دورية أكاديمية
أعرض في EDS

Impact of Tissue Enolase 1 Protein Overexpression in Esophageal Cancer Progression.

التفاصيل البيبلوغرافية
العنوان: Impact of Tissue Enolase 1 Protein Overexpression in Esophageal Cancer Progression.
المؤلفون: Hoang AT; Department of Medical Sciences, University of Turin, 10126 Turin, Italy., Vizio B; Department of Medical Sciences, University of Turin, 10126 Turin, Italy., Chiusa L; Pathology Unit, AOU City of Health and Science of Turin, 10126 Turin, Italy., Cimino A; Pathology Unit, AOU City of Health and Science of Turin, 10126 Turin, Italy., Solerio D; Department of Surgical Sciences, University of Turin, Unit of Digestive and Oncological Surgery 1U, AOU City of Health and Science of Turin, 10126 Turin, Italy., Do NH; Vietnam National Institute of Ophthalmology, Hanoi, Vietnam., Pileci S; Department of Surgical Sciences, University of Turin, Unit of Digestive and Oncological Surgery 1U, AOU City of Health and Science of Turin, 10126 Turin, Italy., Camandona M; Department of Surgical Sciences, University of Turin, Unit of Digestive and Oncological Surgery 1U, AOU City of Health and Science of Turin, 10126 Turin, Italy., Bellone G; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
المصدر: International journal of medical sciences [Int J Med Sci] 2021 Jan 26; Vol. 18 (6), pp. 1406-1414. Date of Electronic Publication: 2021 Jan 26 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101213954 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-1907 (Electronic) Linking ISSN: 14491907 NLM ISO Abbreviation: Int J Med Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Australia] : Ivyspring International Publisher, c2004-
مواضيع طبية MeSH: Adenocarcinoma/*genetics , Barrett Esophagus/*pathology , Biomarkers, Tumor/*genetics , DNA-Binding Proteins/*genetics , Esophageal Neoplasms/*genetics , Esophageal Squamous Cell Carcinoma/*genetics , Phosphopyruvate Hydratase/*genetics , Tumor Suppressor Proteins/*genetics, Adenocarcinoma/blood ; Adenocarcinoma/diagnosis ; Adenocarcinoma/mortality ; Adult ; Aged ; Aged, 80 and over ; Barrett Esophagus/blood ; Barrett Esophagus/diagnosis ; Barrett Esophagus/genetics ; Biomarkers, Tumor/analysis ; Biopsy ; Case-Control Studies ; Disease Progression ; Esophageal Mucosa/pathology ; Esophageal Neoplasms/blood ; Esophageal Neoplasms/diagnosis ; Esophageal Neoplasms/mortality ; Esophageal Squamous Cell Carcinoma/blood ; Esophageal Squamous Cell Carcinoma/diagnosis ; Esophageal Squamous Cell Carcinoma/mortality ; Female ; Gene Expression Regulation, Neoplastic ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Neoplasm Staging
مستخلص: Enolase (ENO) 1 is a key glycolytic enzyme and important player in tumorigenesis. ENO1 overexpression has been correlated with tumor progression and/or worse prognosis in several solid malignancies. However, data concerning the impact of ENO1 in cancer conflict. The study correlated local and circulating ENO1 protein levels in esophageal cancer (EC) with clinicopathological data, to assess its potential clinical value. ENO1 expression was analyzed by immunohistochemistry in paired tumor and non-tumor tissue samples from 40 EC cases and mucosal biopsies from 45 Barrett's esophagus (BE) cases, plus in plasma from these patients and 25 matched healthy controls. ENO1 was abnormally elevated in cancer-cell cytoplasm in both EC types, in esophageal squamous cell carcinoma and in adenocarcinoma (EAC), increasing significantly with tumor stage progression and the transition from BE to EAC. EAC patients exhibited significantly lower ENO1 plasma concentrations than normal subjects. Neither local nor systemic ENO1 expression levels were significantly associated with overall survival. These results indicate ENO1 as potential biomarker, delineating a population of patients with Barrett's esophagus at high risk of cancer, and as new therapeutic opportunity in EC patient management. However, further confirmation might be necessary.
Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
(© The author(s).)
References: World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):438-49. (PMID: 25400987)
J Hematol Oncol. 2015 Mar 08;8:22. (PMID: 25887760)
J Clin Invest. 2006 Jan;116(1):271-84. (PMID: 16395409)
Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998)
Int J Oncol. 2016 Jul;49(1):393-401. (PMID: 27210467)
Cancer Res. 2006 Dec 15;66(24):11907-12. (PMID: 17178888)
Pathologe. 1987 May;8(3):138-40. (PMID: 3303008)
Cancer Lett. 2005 Dec 18;230(2):187-98. (PMID: 16297705)
Lancet. 2017 Nov 25;390(10110):2383-2396. (PMID: 28648400)
Mol Cell Biol. 1991 Apr;11(4):2154-61. (PMID: 2005901)
Oncotarget. 2018 Aug 28;9(67):32795-32809. (PMID: 30214685)
Anim Nutr. 2016 Mar;2(1):12-17. (PMID: 29767008)
J Bras Pneumol. 2018 Jan-Feb;44(1):18-23. (PMID: 29538538)
Surg Today. 2006;36(12):1085-93. (PMID: 17123137)
Cancer Manag Res. 2018 Nov 15;10:5735-5745. (PMID: 30532594)
Eur J Cancer. 2010 Jun;46(9):1712-23. (PMID: 20435467)
CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
Clin Cancer Res. 2006 Oct 1;12(19):5746-54. (PMID: 17020980)
Gastroenterol Res Pract. 2018 Feb 1;2018:3842198. (PMID: 29483925)
Am J Surg Pathol. 2016 May;40(5):e45-66. (PMID: 26813745)
Oncotarget. 2015 Jun 20;6(17):15610-27. (PMID: 25951350)
FEBS Lett. 2000 May 4;473(1):47-52. (PMID: 10802057)
Proteomics. 2006 Apr;6 Suppl 1:S293-9. (PMID: 16521150)
Oncologist. 2015 Oct;20(10):1132-9. (PMID: 26336083)
Int J Oncol. 2008 Oct;33(4):725-31. (PMID: 18813785)
Int J Oncol. 2011 Feb;38(2):375-83. (PMID: 21165559)
Mol Cell Biol. 2008 Aug;28(15):4829-42. (PMID: 18490439)
Exp Cell Res. 2015 Jul 15;335(2):216-23. (PMID: 26024773)
Int J Clin Exp Med. 2015 Jan 15;8(1):231-9. (PMID: 25784992)
Oncotarget. 2015 May 10;6(13):11098-113. (PMID: 25860938)
Cell Mol Life Sci. 2001 Jun;58(7):902-20. (PMID: 11497239)
Semin Radiat Oncol. 2007 Jan;17(1):38-44. (PMID: 17185196)
Cancer Res. 2009 Jul 1;69(13):5285-8. (PMID: 19549904)
Ann Cardiothorac Surg. 2017 Mar;6(2):119-130. (PMID: 28447000)
Lancet Oncol. 2015 Sep;16(9):1090-1098. (PMID: 26254683)
Cancer Chemother Pharmacol. 2000;46 Suppl:S86-90. (PMID: 10950155)
Acta Crystallogr D Biol Crystallogr. 2008 Jun;64(Pt 6):651-7. (PMID: 18560153)
J Biomed Biotechnol. 2012;2012:156795. (PMID: 23118496)
Oncotarget. 2017 Jul 18;8(29):47691-47708. (PMID: 28548950)
Mol Carcinog. 2017 May;56(5):1427-1437. (PMID: 27996156)
Zhongguo Fei Ai Za Zhi. 2010 Dec;13(12):1089-93. (PMID: 21159241)
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Jun;25(12):554-6. (PMID: 21950004)
Ann Cardiothorac Surg. 2017 Mar;6(2):99-109. (PMID: 28446998)
Breast Cancer Res Treat. 2010 Jun;121(3):539-53. (PMID: 19655245)
Mol Cancer. 2014 Mar 21;13:65. (PMID: 24650096)
فهرسة مساهمة: Keywords: Barrett's esophagus; Enolase 1; esophageal cancer; tumor progression.
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (DNA-Binding Proteins)
0 (Tumor Suppressor Proteins)
EC 4.2.1.11 (ENO1 protein, human)
EC 4.2.1.11 (Phosphopyruvate Hydratase)
SCR Disease Name: Adenocarcinoma Of Esophagus
تواريخ الأحداث: Date Created: 20210225 Date Completed: 20211018 Latest Revision: 20211018
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7893569
DOI: 10.7150/ijms.52688
PMID: 33628097
قاعدة البيانات: MEDLINE
الوصف
تدمد:1449-1907
DOI:10.7150/ijms.52688